News Sentiment

ANVS sentiment intelligence

Annovis Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 64 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.86 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.6% over one week, +4.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -3.6% Price reacting lower
Trend fit Trend inactive 4.5% over four weeks
Fair value -68.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 39
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingView 7
Investing.com 7
GlobeNewswire 5
The Globe and Mail 3
Moomoo 3
ad-hoc-news.de 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 18
Regulatory and legal 4
Analyst action 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
TradingView Direct company coverage

Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled

Annovis Bio (ANVS) has fully enrolled 850 pTau217-confirmed early Alzheimer's disease patients in its pivotal Phase 3 buntanetap trial across 83 U.S. sites. The trial is randomized, placebo-controlled, and double-blind, with primary endpoints of ADAS-Cog13 and ADCS-iADL. Dual rea

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 10:39
Source
TradingView
Stock Titan Direct company coverage

Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study

Annovis Bio has announced the full enrollment of 850 patients in its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer's disease. The trial, exceeding original enrollment projections, will feature two separate data readouts: a 6-month sympt

Tone
Positive 75/100
Event
Regulatory and legal
Published
10 Jul 2026 09:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)

This article highlights two healthcare stocks, Evolus (EOLS) and Annovis Bio (ANVS), that analysts are bullish on. Evolus received a Buy rating and a $15.00 price target from Mizuho Securities, with a consensus of Strong Buy. Annovis Bio also maintained a Buy rating and an $8.00

Tone
Positive 71/100
Event
Analyst action
Published
09 Jul 2026 20:14
Source
The Globe and Mail
MyChesCo Direct company coverage

Annovis Promotes Research Chief as Lead Drug Nears Key Trial

Annovis Bio has promoted Cheng Fang to Chief Scientific Officer as the company advances its lead drug candidate, buntanetap, towards key clinical and regulatory milestones for Alzheimer's disease. Fang will oversee scientific strategy, clinical development, and regulatory interac

Tone
Positive 72/100
Event
Regulatory and legal
Published
08 Jul 2026 11:09
Source
MyChesCo
Bitget Direct company coverage

The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified.

Annovis Bio Inc. has provided a clarified timeline for its key clinical trial data readouts. Results concerning symptom improvement efficacy are anticipated in the first quarter of 2027, while data evaluating the drug's impact on disease progression is expected in the first quart

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 13:11
Source
Bitget
Moomoo Direct company coverage

Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease

Annovis Bio has successfully completed patient enrollment for its Phase 3 clinical trial evaluating buntanetap in patients with early Alzheimer's disease. The trial has fully enrolled 325 subjects across 50 sites, with topline results anticipated in the first quarter of 2027. Thi

Tone
Positive 66/100
Event
Earnings
Published
07 Jul 2026 12:10
Source
Moomoo
Investing.com Direct company coverage

Annovis Bio completes enrollment in phase 3 Alzheimer’s trial

Annovis Bio Inc. has successfully completed the enrollment of 850 patients in its pivotal Phase 3 clinical trial for buntanetap, a treatment for early Alzheimer’s disease. The trial, exceeding its original enrollment target, will have two key data readouts: a 6-month analysis of

Tone
Positive 67/100
Event
Analyst action
Published
07 Jul 2026 11:08
Source
Investing.com
Stock Titan Direct company coverage

Annovis enrolls 850 patients in Phase 3 Alzheimer’s study

Annovis Bio (NYSE: ANVS) has fully enrolled 850 pTau217-positive patients in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer’s disease across 83 US sites. The dual-design study aims for 6-month symptomatic data by Q1 2027 and 18-month disease-modifying data by Q1

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 11:00
Source
Stock Titan
GlobeNewswire Direct company coverage

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Annovis Bio Inc. has fully enrolled its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer’s disease, with 850 patients participating across 83 sites in the US. The trial aims to evaluate both symptomatic and disease-modifying effects, with

Tone
Positive 74/100
Event
Regulatory and legal
Published
07 Jul 2026 11:00
Source
GlobeNewswire
Market source Direct company coverage

Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial

Annovis Bio announced the enrollment of over 850 patients for its upcoming Alzheimer's Disease trial. Sarah MacCallum and Cheng Fang from Annovis Bio discussed this development with Ashley Mastronardi on NYSE Live.

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 10:51
Source
Market source
GlobeNewswire Direct company coverage

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Annovis Bio, Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer. Dr. Fang will lead the company's scientific strategy and research operations for its Alzheimer's and Parkinson's disease programs. Her promotion is critical as Annovis advances its lead drug candidate, bun

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 21:09
Source
GlobeNewswire
Investing.com Direct company coverage

Annovis Bio promotes Cheng Fang to chief scientific officer

Annovis Bio Inc. has promoted Cheng Fang to Chief Scientific Officer. Fang will oversee the scientific strategy and research operations for the company's Alzheimer's and Parkinson's disease programs. This promotion comes as Annovis Bio advances its investigational oral therapy, b

Tone
Positive 61/100
Event
Regulatory and legal
Published
01 Jul 2026 12:41
Source
Investing.com
citybiz Direct company coverage

Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones

Annovis Bio Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer, recognizing her expanded leadership role as the company approaches critical Phase 3 milestones for its lead drug candidate, buntanetap. Dr. Fang will now oversee scientific strategy and research operations

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 12:40
Source
citybiz
Stock Titan Direct company coverage

Annovis elevates its R&D chief as Phase 3 Alzheimer’s data nears

Annovis Bio, Inc. has promoted Cheng Fang, Ph.D., to Chief Scientific Officer to lead scientific strategy and research operations for its Alzheimer’s and Parkinson’s programs. This promotion comes as the company approaches key milestones, including the release of top-line data fr

Tone
Positive 65/100
Event
Market update
Published
01 Jul 2026 11:40
Source
Stock Titan
Finviz Direct company coverage

ANVS - Annovis Bio Inc Latest SEC Filings

This article provides detailed financial data and performance metrics for Annovis Bio Inc (ANVS), including its latest stock close, market capitalization, income, sales, and various valuation ratios. It also highlights insider and institutional ownership, short interest, and key

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:40
Source
Finviz
www.marketscreener.com Direct company coverage

Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index

Annovis Bio, Inc. (NYSE: ANVS) has been added to the Russell Microcap Index. The company is a late-stage clinical drug platform company focused on neurodegenerative diseases like Alzheimer's and Parkinson's, developing product candidates such as Buntanetap, ANVS405, and ANVS301.

Tone
Positive 62/100
Event
Market update
Published
29 Jun 2026 05:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index

Annovis Bio, Inc. (NYSE: ANVS), a biotechnology company focused on neurodegenerative diseases, has been added to both the Russell 3000E Index and the Russell Microcap Index. This inclusion is a significant milestone, potentially increasing the company's visibility and attracting

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 02:43
Source
www.marketscreener.com
TradingView Direct company coverage

Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X)

This article provides an overview of Annovis Bio Inc (TRADEGATE:07X) financials and analyst estimates. It details the company's past earnings and revenue, future earnings forecasts, and historical stock performance including its all-time high and low prices. The article also conf

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:41
Source
TradingView
Moomoo Direct company coverage

Annovis Bio | DEFA14A: Others

This article is a DEFA14A filing by Annovis Bio. DEFA14A filings are definitive additional soliciting materials filed with the SEC. The content of this specific filing is "Document".

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:10
Source
Moomoo
TradingView Direct company coverage

Annovis Bio Inc Actuals & Estimates (FWB:07X)

This article provides financial actuals and estimates for Annovis Bio Inc (FWB:07X), including analyst price targets, historical stock prices, and upcoming earnings dates. It highlights that the company's stock ticker on the FWB exchange is 07X and details past earnings performan

Tone
Negative 40/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS

The document displays financial information for Annovis Bio, Inc. (NYSE: ANVS), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades at the time of viewing. The content primarily comes from TradingView, with market and

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS

This article provides financial information for Annovis Bio, Inc. (NYSE:ANVS), specifically focusing on its enterprise value to revenue forward ratio. The content is primarily a data point or financial metric display from TradingView, which indicates the company's valuation relat

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 15:41
Source
TradingView
TradingKey Direct company coverage

Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Annovis Bio Inc (ANVS), detailing its support, resistance, indicators, and moving averages. According to the analysis, various indicators like MACD and TRIX show sell signals, along with all moving averages from MA5 to MA200. The over

Tone
Negative 29/100
Event
Market update
Published
21 Jun 2026 17:10
Source
TradingKey
The Globe and Mail Direct company coverage

Annovis Bio Shareholders Approve Governance and Compensation Changes

Annovis Bio shareholders approved significant governance and compensation changes at their 2026 Annual Meeting, including the election of all five director nominees and the ratification of Ernst & Young LLP as auditor. Investors also approved an amendment to the 2019 Equity Incen

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 15:38
Source
The Globe and Mail